Clicky

Hoth Therapeutics, Inc.(HOTH)

Description: Hoth Therapeutics Inc., a Nevada corporation, is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. Hoth has exclusive worldwide rights to the BioLexa Platform. Hoth intends to use the BioLexa Platform to develop two different topical cream products: (i) a product to treat eczema and (ii) a product that reduces post-procedure infections, accelerates healing and improves clinical outcomes for patients undergoing aesthetic dermatology procedures. Hoth’s initial focus will be on the development of the BioLexa Platform for the treatment of eczema. Eczema is a disease that results in inflammation of the skin and is characterized by rash, red skin, and itchiness. Eczema is also referred to as atopic dermatitis.


Keywords: Medicine Disease Immunology Inflammation Dermatology Atopic Dermatitis Dermatitis Healing Eczema Type I Hypersensitivity Atopy Itchiness Sodium Hypochlorite Washes

Home Page: www.hoththerapeutics.com

HOTH Technical Analysis

1 Rockefeller Plaza
New York, NY 10020
United States
Phone: 646 756 2997


Officers

Name Title
Mr. Robb Knie Pres, CEO & Chairman
Ms. Jane H. Springer VP of Operations
Dr. Stefanie Johns Ph.D. Chief Scientific Officer
Mr. David S. Briones Chief Financial Officer
Hayley Springer Exec. VP of Operations

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4802
Price-to-Sales TTM: 0
IPO Date: 2019-02-15
Fiscal Year End: December
Full Time Employees: 4
Back to stocks